US Pharma MarketingEvogene and ELEO to develop new oral PCSK9 inhibitors
Evogene and ELEO have entered into a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia and cardiovascular diseases.
Evogene and ELEO have entered into a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia and cardiovascular diseases.
Source: Pharmaceutical Technology